A study by Moens2 explored how Symprove can facilitate delivery of viable probiotic bacteria to the gut and measured the effect of colonisation and proliferation of specific probiotic species on the human gut microbiota, using an in vitro gut model. The data revealed immediate colonisation and growth of three probiotic species in the luminal and mucosal compartments of the proximal and distal colon, and growth of a fourth species in the luminal proximal colon, leading to higher proximal and distal colonic lactate concentrations. The lactate stimulated growth of lactate-consuming bacteria, altering the bacterial diversity of the microbiota and resulting in increased short-chain fatty acid production, especially butyrate. Additionally, an immunomodulatory effect of the probiotics was seen; production of anti-inflammatory cytokines (IL-6 and IL-10) was increased and production of inflammatory chemokines (MCP-1, CXCL 10 and IL-8.) was reduced.
The results indicate that the probiotic species facilitate modulation of the gut microbiota composition and metabolic activity thereby influencing the immune response.